Literature DB >> 28860066

Novel peptide MT23 for potent penetrating and selective targeting in mouse melanoma cancer cells.

Nan Zhou1, Jiao Wu2, Yan-Yan Qin2, Xue-Li Zhao2, Yi Ding2, Li-Sha Sun2, Tong He3, Xiao-Wen Huang4, Chang-Bai Liu5, Hu Wang6.   

Abstract

Cell-penetrating peptides (CPPs) have a great potential for intracellular delivery of cell-impermeable biological macromolecules in clinical therapy. However, their lack of cell and tissue specificity remains the primary limitation for their clinical development as drug delivery vehicles. In this study, based on phage display and an in silico approach, we found a novel CPP-MT23 with mouse melanoma cell specificity, it can only enter B16 melanoma cancer cells and without any cytotoxicity, Moreover, MT23 showed higher penetration efficiency based on fluorescence microcopy and quantitative assay, and it has capability for mediating functional Apoptin into cells in vitro or in vivo. Moreover, MT23-Apoptin can significantly inhibit tumor growth and induce the cell apoptosis in B16 tumor bearing mice. To sum up, all the results implicated that MT23 has the potential to deliver exogenous therapeutic proteins for further use and it also expected to lay the foundation for developing human melanoma cancer cell specific CPP.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cell penetrating peptide; Drug target; Melanoma cancer cell

Mesh:

Substances:

Year:  2017        PMID: 28860066     DOI: 10.1016/j.ejpb.2017.08.011

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  8 in total

1.  Intracellular Delivery of DNA and Protein by a Novel Cell-Permeable Peptide Derived from DOT1L.

Authors:  Jingping Geng; Xiangli Guo; Lidan Wang; Richard Q Nguyen; Fengqin Wang; Changbai Liu; Hu Wang
Journal:  Biomolecules       Date:  2020-02-02

Review 2.  Cancer Treatment Goes Viral: Using Viral Proteins to Induce Tumour-Specific Cell Death.

Authors:  Jasmine Wyatt; Manuel M Müller; Mahvash Tavassoli
Journal:  Cancers (Basel)       Date:  2019-12-07       Impact factor: 6.639

3.  Improved transfer efficiency of supercharged 36 + GFP protein mediate nucleic acid delivery.

Authors:  Lidan Wang; Jingping Geng; Linlin Chen; Xiangli Guo; Tao Wang; Yanfen Fang; Bonn Belingon; Jiao Wu; Manman Li; Ying Zhan; Wendou Shang; Yingying Wan; Xuemei Feng; Xianghui Li; Hu Wang
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

4.  In silico identification and experimental validation of cellular uptake and intracellular labeling by a new cell penetrating peptide derived from CDN1.

Authors:  Xiangli Guo; Linlin Chen; Lidan Wang; Jingping Geng; Tao Wang; Jixiong Hu; Jason Li; Changbai Liu; Hu Wang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

Review 5.  Overcoming the cellular barriers and beyond: Recent progress on cell penetrating peptide modified nanomedicine in combating physiological and pathological barriers.

Authors:  Yingke Liu; Zhihe Zhao; Man Li
Journal:  Asian J Pharm Sci       Date:  2022-06-23       Impact factor: 9.273

Review 6.  Viral Proteins as Emerging Cancer Therapeutics.

Authors:  Ekta Manocha; Arnaldo Caruso; Francesca Caccuri
Journal:  Cancers (Basel)       Date:  2021-05-03       Impact factor: 6.639

7.  TRP Channels Interactome as a Novel Therapeutic Target in Breast Cancer.

Authors:  María Paz Saldías; Diego Maureira; Octavio Orellana-Serradell; Ian Silva; Boris Lavanderos; Pablo Cruz; Camila Torres; Mónica Cáceres; Oscar Cerda
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

8.  In silico identification and experimental validation of cellular uptake by a new cell penetrating peptide P1 derived from MARCKS.

Authors:  Linlin Chen; Xiangli Guo; Lidan Wang; Jingping Geng; Jiao Wu; Bin Hu; Tao Wang; Jason Li; Changbai Liu; Hu Wang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.